JM-010 is approved to start Phase IIa clinical-proof-of concept studies.
It is developed based on Contera Pharma’s new approach to identify and develop new treatment for patients suffering from serious disorders.
JM-010 is developed based on a poly-pharmacological approach to treat or prevent L-DOPA induced dyskinesia.
This will provide efficacy reducing involuntary movement without adverse effects.
JM-010 has shown very convincing efficacy in preclinical studies both acutely and after sub-chronic administration.
JM-010 is covered by several very strong patent applications to provide exclusivity until 2032 or later.